Mycofenolzuur Accord (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Mycofenolzuur Accord, is an antiproliferative immunosuppressant presented as an oral formulation for oral use. It prevents organ transplant rejection and treats lupus nephritis in transplant recipients and patients with autoimmune disease.

GNH USA supplies Mycofenolzuur Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycofenolzuur Accord (mycophenolic acid) is used in immunosuppressive therapy to inhibit lymphocyte proliferation.

- Renal transplant rejection: helps prevent acute and chronic rejection in kidney transplant recipients. - Cardiac transplant rejection: reduces the risk of graft rejection after heart transplantation. - Hepatic transplant rejection: supports maintenance of graft function in liver transplant patients. - Lupus nephritis: contributes to disease control in patients with systemic lupus erythematosus affecting the kidneys.

Mycofenolzuur Accord may be associated with a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Hypertension: elevated blood pressure requiring monitoring. - Infections: increased susceptibility to common bacterial or viral infections. - Tremor: mild shaking of hands or limbs.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells. - Anemia: decreased red blood cell count causing fatigue. - Severe infections: opportunistic infections such as CMV or fungal disease. - Malignancy: increased risk of certain cancers with long‑term use. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Pregnancy loss: teratogenic effects leading to fetal harm.

Careful monitoring and patient counseling are essential when using Mycofenolzuur Accord.

- Monitor blood counts: perform regular complete blood count tests to detect leukopenia or anemia. - Assess renal function: adjust therapy based on creatinine clearance and kidney health. - Avoid use in pregnancy: category X indicates known fetal risk; contraindicated. - Avoid live vaccines: immunosuppression can lead to vaccine‑derived infection. - Adjust dose in hepatic impairment: consider reduced dosing for patients with liver disease. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mycofenolzuur Accord can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Live vaccines: increased risk of infection due to immunosuppression. - Azathioprine: additive bone‑marrow suppression leading to severe cytopenias. - Rituximab: enhanced immunosuppressive effect, raising infection risk.

Moderate Interactions (Monitor Closely): - Antacids (e.g., aluminum hydroxide): may reduce mycophenolic acid absorption. - CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations, requiring dose adjustment. - CYP3A4 inducers (e.g., rifampin): decrease drug levels, potentially reducing efficacy.